Today, the American Diabetes Association® (ADA) announced a new suite of resources to support improved care for those living with obesity. The resources are part of a nationwide collaboration between ...

Background Aortic stenosis is a degenerative condition with high mortality in its severe stages and no preventive treatment.

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

A weekly diabetes medication may replace painful daily hormone injections for patients with congenital generalised lipodystrophy (CGL). Early findings suggest that tirzepatide – used for diabetes and ...

In most cases, your doctor will start by prescribing oral medication. Metformin is the first-line treatment for the majority of people with type 2 diabetes. Over time, you might need to add other ...

Different methods employ different definitions. Chart-review studies define medication errors as errors in the ordering, transcribing, dispensing, administering, or monitoring of a medication.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Retatrutide targets GIP and GLP-1 – the same as Lilly’s fast-growing diabetes ... ADA, Pfizer revealed that it had decided to end the development of one of its once-daily oral GLP-1 agonist ...

Let’s uncover what the future holds for Cardano. The 1-day Cardano (ADA/USD) chart on February 2 reveals bearish momentum, with the current price at $0.8926 nearing the lower Bollinger Band at $0.8565 ...

In addition to charts, medication order sheets and medication administration records (MARs) are reviewed daily. Voluntary and solicited reports are obtained from staff. Finally, additional sources ...

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...